Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy (Archive)
Wegovy pill expands US obesity share, but cash flow limits and GLP‑1 competition constrain upside.
This 5-Minute Pitch was originally published on Seeking Alpha. It is shared here to showcase my work and track record. I also publish full 5-Minute Pitches on this site. This will be behind a paywall, accessible to Hunter Tier members.
Elevator Pitch
- Wegovy pill’s fast US uptake expands Novo Nordisk’s obesity market and slows down the pace of profit degrowth.
- CagriSema’s late 2026 US regulatory decision is a key R&D catalyst, despite weaker commercial positioning versus Eli Lilly's corresponding drug.
- Rising net working capital days due to lower payable days is leading to a deterioration in cash flow conversion. This is a key risk to watch.
- NVO trades below typical peers' 1-yr fwd PE multiples, but earnings growth expectations remain soft, limiting upside conviction.
- The charts show NVO holding major support with fading selling pressure, yet no clear bullish engulf signal. This implies likely consolidation ahead.
Read the full article here.
